Plant ID: NPO26763
Plant Latin Name: Rhododendron micranthum
Taxonomy Genus: Rhododendron
Taxonomy Family: Ericaceae
NCBI TaxonomyDB:
118363
Plant-of-the-World-Online:
n.a.
China
NPSR1; | |
ALPL; ALOX12; HSD17B2; HSD17B10; NOX4; APEX1; POLB; | |
MET; FLT3; CDK1; PIM1; AXL; KDR; IGF1R; AURKB; | |
CA12; CA9; CA7; | |
TYR; | |
AHR; NFKB1; |
Protein Class | Gene ID | Protein Name | Uniprot ID | Target ChEMBL ID |
---|---|---|---|---|
Cytochrome P450 family 1 | CYP1A2 | Cytochrome P450 1A2 | P05177 | CHEMBL3356 |
Cytochrome P450 family 1 | CYP1B1 | Cytochrome P450 1B1 | Q16678 | CHEMBL4878 |
Cytochrome P450 family 1 | CYP1A1 | Cytochrome P450 1A1 | P04798 | CHEMBL2231 |
Enzyme_unclassified | ALPL | Alkaline phosphatase, tissue-nonspecific isozyme | P05186 | CHEMBL5979 |
Enzyme_unclassified | ALOX12 | Arachidonate 12-lipoxygenase | P18054 | CHEMBL3687 |
Enzyme_unclassified | HSD17B2 | Estradiol 17-beta-dehydrogenase 2 | P37059 | CHEMBL2789 |
Enzyme_unclassified | HSD17B10 | Endoplasmic reticulum-associated amyloid beta-peptide-binding protein | Q99714 | CHEMBL4159 |
Enzyme_unclassified | NOX4 | NADPH oxidase 4 | Q9NPH5 | CHEMBL1250375 |
Enzyme_unclassified | APEX1 | DNA-(apurinic or apyrimidinic site) lyase | P27695 | CHEMBL5619 |
Enzyme_unclassified | POLB | DNA polymerase beta | P06746 | CHEMBL2392 |
Lyase | CA12 | Carbonic anhydrase XII | O43570 | CHEMBL3242 |
Lyase | CA9 | Carbonic anhydrase IX | Q16790 | CHEMBL3594 |
Lyase | CA7 | Carbonic anhydrase VII | P43166 | CHEMBL2326 |
Oxidoreductase | TYR | Tyrosinase | P14679 | CHEMBL1973 |
Peptide receptor (family A GPCR) | NPSR1 | Neuropeptide S receptor | Q6W5P4 | CHEMBL5162 |
Protein Kinase | MET | Hepatocyte growth factor receptor | P08581 | CHEMBL3717 |
Protein Kinase | FLT3 | Tyrosine-protein kinase receptor FLT3 | P36888 | CHEMBL1974 |
Protein Kinase | CDK1 | Cyclin-dependent kinase 1 | P06493 | CHEMBL308 |
Protein Kinase | PIM1 | Serine/threonine-protein kinase PIM1 | P11309 | CHEMBL2147 |
Protein Kinase | AXL | Tyrosine-protein kinase receptor UFO | P30530 | CHEMBL4895 |
Protein Kinase | KDR | Vascular endothelial growth factor receptor 2 | P35968 | CHEMBL279 |
Protein Kinase | IGF1R | Insulin-like growth factor I receptor | P08069 | CHEMBL1957 |
Protein Kinase | AURKB | Serine/threonine-protein kinase Aurora-B | Q96GD4 | CHEMBL2185 |
Transcription Factor | AHR | Aryl hydrocarbon receptor | P35869 | CHEMBL3201 |
Transcription Factor | NFKB1 | Nuclear factor NF-kappa-B p105 subunit | P19838 | CHEMBL3251 |
GO Type | GO Category | Enriched GO Terms | p-Value | Adjusted p-Value | Enriched Genes |
---|---|---|---|---|---|
BP | GO:0009987; cellular process | GO:0071407; cellular response to organic cyclic compound | 2.235E-07 | 2.261E-04 | ALPL, APEX1, CYP1A1, CYP1B1, FLT3, NFKB1, NOX4 |
BP | GO:0008152; metabolic process | GO:0097267; omega-hydroxylase P450 pathway | 2.284E-07 | 2.261E-04 | CYP1A1, CYP1A2, CYP1B1 |
MF | GO:0005488; binding | GO:0019825; oxygen binding | 3.136E-07 | 2.846E-04 | CYP1A1, CYP1A2, CYP1B1, NOX4 |
BP | GO:0032502; developmental process | GO:0007568; aging | 4.014E-07 | 3.496E-04 | APEX1, AURKB, CDK1, CYP1A1, NOX4, POLB |
MF | GO:0003824; catalytic activity | GO:0004089; carbonate dehydratase activity | 8.625E-07 | 6.260E-04 | CA12, CA7, CA9 |
BP | GO:0008152; metabolic process | GO:0055114; oxidation-reduction process | 1.015E-06 | 6.700E-04 | ALOX12, APEX1, CYP1A1, CYP1A2, CYP1B1, HSD17B10, HSD17B2, NOX4, TYR |
BP | GO:0009987; cellular process | GO:0070301; cellular response to hydrogen peroxide | 1.083E-06 | 6.740E-04 | APEX1, AXL, CDK1, CYP1B1 |
BP | GO:0009987; cellular process | GO:0006286; base-excision repair, base-free sugar-phosphate removal | 1.608E-06 | 8.541E-04 | APEX1, POLB |
BP | GO:0008152; metabolic process | GO:0019373; epoxygenase P450 pathway | 2.508E-06 | 1.241E-03 | CYP1A1, CYP1A2, CYP1B1 |
BP | GO:0008152; metabolic process | GO:0009404; toxin metabolic process | 3.334E-06 | 1.472E-03 | CYP1A1, CYP1A2, CYP1B1 |
MF | GO:0003824; catalytic activity | GO:0070330; aromatase activity | 3.334E-06 | 1.472E-03 | CYP1A1, CYP1A2, CYP1B1 |
BP | GO:0008152; metabolic process | GO:0018108; peptidyl-tyrosine phosphorylation | 3.565E-06 | 1.517E-03 | AXL, FLT3, IGF1R, KDR, MET |
BP | GO:0065007; biological regulation | GO:0042592; homeostatic process | 3.652E-06 | 1.517E-03 | ALOX12, APEX1, AXL, CA12, CA7, FLT3, MET, NOX4, NPSR1, POLB |
BP | GO:0008152; metabolic process | GO:0046777; protein autophosphorylation | 4.604E-06 | 1.671E-03 | AURKB, FLT3, IGF1R, KDR, PIM1 |
BP | GO:0009987; cellular process | GO:0043066; negative regulation of apoptotic process | 8.012E-06 | 2.572E-03 | ALOX12, AURKB, AXL, CDK1, IGF1R, KDR, NFKB1, PIM1 |
BP | GO:0008152; metabolic process | GO:0018894; dibenzo-p-dioxin metabolic process | 9.634E-06 | 2.914E-03 | CYP1A1, CYP1A2 |
BP | GO:0008152; metabolic process | GO:0006730; one-carbon metabolic process | 1.329E-05 | 3.711E-03 | CA12, CA7, CA9 |
MF | GO:0005488; binding | GO:0020037; heme binding | 2.089E-05 | 5.481E-03 | CYP1A1, CYP1A2, CYP1B1, NOX4 |
BP | GO:0051179; localization | GO:0015701; bicarbonate transport | 2.449E-05 | 6.220E-03 | CA12, CA7, CA9 |
BP | GO:0050896; response to stimulus | GO:0032496; response to lipopolysaccharide | 2.457E-05 | 6.220E-03 | ALPL, AXL, CYP1A1, CYP1A2, NFKB1 |
MF | GO:0060089; molecular transducer activity | GO:0005021; vascular endothelial growth factor-activated receptor activity | 3.364E-05 | 8.257E-03 | FLT3, KDR |
BP | GO:0050896; response to stimulus | GO:0010243; response to organonitrogen compound | 3.730E-05 | 8.926E-03 | APEX1, CDK1, FLT3, IGF1R, NFKB1, NOX4, TYR |
CC | GO:0043226; organelle | GO:0005876; spindle microtubule | 4.299E-05 | 9.958E-03 | AURKB, CDK1, POLB |
Pathway Category Top Level | Pathway Category Second Level | Pathway ID | Pathway Name | p-Value | Adjusted p-Value | Enriched Genes |
---|---|---|---|---|---|---|
09150 Organismal Systems | 09152 Endocrine system | hsa04913 | Ovarian steroidogenesis | 4.205E-07 | 3.771E-05 | HSD17B2, CYP1A1, CYP1B1, IGF1R |
09100 Metabolism | 09103 Lipid metabolism | hsa00140 | Steroid hormone biosynthesis | 7.696E-07 | 3.771E-05 | CYP1A2, HSD17B2, CYP1A1, CYP1B1 |
09100 Metabolism | 09105 Amino acid metabolism | hsa00380 | Tryptophan metabolism | 1.653E-05 | 4.051E-04 | CYP1A2, CYP1A1, CYP1B1 |
09160 Human Diseases | 09161 Cancers | hsa05221 | Acute myeloid leukemia | 4.828E-05 | 9.463E-04 | FLT3, PIM1, NFKB1 |
09100 Metabolism | 09102 Energy metabolism | hsa00910 | Nitrogen metabolism | 1.160E-06 | 3.788E-05 | CA12, CA7, CA9 |
09130 Environmental Information Processing | 09132 Signal transduction | hsa04014 | Ras signaling pathway | 1.695E-04 | 1.846E-03 | KDR, MET, NFKB1, IGF1R |
09160 Human Diseases | 09161 Cancers | hsa05202 | Transcriptional misregulation in cancer | 6.924E-05 | 1.131E-03 | FLT3, MET, NFKB1, IGF1R |
09100 Metabolism | 09111 Xenobiotics biodegradation and metabolism | hsa00980 | Metabolism of xenobiotics by cytochrome P450 | 1.013E-04 | 1.418E-03 | CYP1A2, CYP1A1, CYP1B1 |
09160 Human Diseases | 09161 Cancers | hsa05204 | Chemical carcinogenesis | 1.431E-04 | 1.754E-03 | CYP1A2, CYP1A1, CYP1B1 |
Unclassified | Unclassified | hsa01100 | Metabolic pathways | 6.157E-04 | 5.486E-03 | HSD17B2, CYP1A2, CYP1A1, ALPL, ALOX12, TYR, HSD17B10 |
09160 Human Diseases | 09161 Cancers | hsa05206 | MicroRNAs in cancer | 4.713E-04 | 4.619E-03 | PIM1, CYP1B1, MET, NFKB1 |
09130 Environmental Information Processing | 09132 Signal transduction | hsa04151 | PI3K-Akt signaling pathway | 7.913E-04 | 5.965E-03 | KDR, MET, NFKB1, IGF1R |
09160 Human Diseases | 09161 Cancers | hsa05200 | Pathways in cancer | 1.390E-03 | 9.731E-03 | FLT3, MET, NFKB1, IGF1R |
09120 Genetic Information Processing | 09124 Replication and repair | hsa03410 | Base excision repair | 7.734E-04 | 5.965E-03 | POLB, APEX1 |
ICD10 Disease Category | Disease Name | ICD10 Code | Associated Disease Targets (Association Ref: TTD database) |
---|---|---|---|
C00-D49: Neoplasms | Pancreatic cancer | C25 | KDR; FLT3; |
G00-G99: Diseases of the nervous system G00-G99 | Pain | G64, G90.0, R52, G89 | CDK1; IGF1R; |
NA: NA | HIV infections | NA | AHR; |
C00-D49: Neoplasms | Biliary cancer | C22, C24 | KDR; |
C00-D49: Neoplasms | Ocular cancer | C69 | APEX1; |
A00-B99: Certain infectious and parasitic diseases | Human immunodeficiency virus infection | B20-B26 | FLT3; |
C00-D49: Neoplasms | Gastrointestinal cancers | C15-C26 | KDR; |
C00-D49: Neoplasms | Cutaneous Melanoma | C43-C44 | KDR; |
I00-I99: Diseases of the circulatory system | Cardiovascular disorder | I00-I99 | KDR; |
G00-G99: Diseases of the nervous system G00-G99 | Motor neurone disease | G12.2 | IGF1R; |
C00-D49: Neoplasms | Multiple myeloma | C90 | IGF1R; AHR; |
Q00-Q99: Congenital malformations, deformations and chromosomal abnormalities | Genetic disease | Q00-Q99 | ALPL; |
C00-D49: Neoplasms | AML | NA | KDR; FLT3; |
L00-L99: Diseases of the skin and subcutaneous tissue | Melasma | L81.1 | TYR; |
C00-D49: Neoplasms | Melanoma | C43 | KDR; TYR; |
C00-D49: Neoplasms | Gliosarcoma | NA | FLT3; |
C00-D49: Neoplasms | Glioma | C71 | KDR; |
C00-D49: Neoplasms | Advanced solid tumor | C00-C75, C7A, C7B | MET; |
J00-J99: Diseases of the respiratory system | Airway inflammation | J00-J99 | FLT3; |
C00-D49: Neoplasms | Peritoneal cavity cancer | NA | KDR; |
E00-E89: Endocrine, nutritional and metabolic diseases | Hormone deficiency | E00-E90 | IGF1R; |
H00-H59: Diseases of the eye and adnexa | Graves' ophthalmopathy | H06.2 | IGF1R; |
I00-I99: Diseases of the circulatory system | Angiogenesis disorder | I00-I99 | KDR; |
C00-D49: Neoplasms | Metastatic HER2-negative gastric cancer | NA | MET; |
I00-I99: Diseases of the circulatory system | Heart disease | I00-I52 | MET; |
NA: NA | Anaplastic mixed oligoastrocytoma | NA | FLT3; |
C00-D49: Neoplasms | Thyroid cancer | C73 | KDR; |
C00-D49: Neoplasms | Lymphoma | C81-C86 | CA9; |
C00-D49: Neoplasms | Colon cancer | C50 | FLT3; ALPL; |
C00-D49: Neoplasms | Colorectal cancer | C18-C21 | IGF1R; KDR; FLT3; |
C00-D49: Neoplasms | Acute myeloid leukemia | C92.0 | AURKB; FLT3; |
C00-D49: Neoplasms | Glioblastoma | NA | FLT3; |
NA: NA | GIST | NA | FLT3; |
C00-D49: Neoplasms | Acute lymphoblastic leukemia | C91.0 | FLT3; |
L00-L99: Diseases of the skin and subcutaneous tissue | Vitiligo | L80 | TYR; |
L00-L99: Diseases of the skin and subcutaneous tissue | Fibrosis | L90.5 | MET; |
C00-D49: Neoplasms | Gastric cancer | C16 | KDR; |
C00-D49: Neoplasms | CLL | NA | FLT3; |
C00-D49: Neoplasms | Fallopian tube cancer | C57.0, D28.2 | KDR; |
C00-D49: Neoplasms | Clear cell renal cell carcinoma | C64 | CA9; |
K00-K95: Diseases of the digestive system | Chemotherapy-induced mucositis | K12.3 | MET; |
C00-D49: Neoplasms | Medullary thyroid cancer | C73 | KDR; |
C00-D49: Neoplasms | Renal cancer | C64 | KDR; CA9; |
C00-D49: Neoplasms | Renal cell carcinoma | NA | KDR; |
C00-D49: Neoplasms | Malignant adrenal gland cancer | C74.0 | IGF1R; |
C00-D49: Neoplasms | Metastatic colorectal cancer | C18-C21 | KDR; |
L00-L99: Diseases of the skin and subcutaneous tissue | Psoriatic disorder | L40 | IGF1R; |
A00-B99: Certain infectious and parasitic diseases | Anthelmintic | B89 | ALPL; |
C00-D49: Neoplasms | Metastatic breast cancer | C50 | KDR; |
C00-D49: Neoplasms | Metastasis | C00-C97 | AXL; |
C00-D49: Neoplasms | Metastatic castration-resistant prostate cancer | C61 | KDR; |
L00-L99: Diseases of the skin and subcutaneous tissue | Psoriasis | L40 | FLT3; |
C00-D49: Neoplasms | Prostate cancer | C61 | FLT3; |
C00-D49: Neoplasms | Breast cancer | C50 | CDK1; IGF1R; KDR; FLT3; CA9; |
E00-E89: Endocrine, nutritional and metabolic diseases | Type 2 diabetes | E11 | NFKB1; |
C00-D49: Neoplasms | Squamous cell cancer of head and neck | NA | KDR; |
C00-D49: Neoplasms | Solid tumours | C00-D48 | MET; AURKB; IGF1R; KDR; FLT3; CA9; |
C00-D49: Neoplasms | Non-small-cell lung cancer | NA | KDR; |
C00-D49: Neoplasms | Non-small cell lung cancer | C33-C34 | MET; IGF1R; KDR; AXL; |
C00-D49: Neoplasms | Advanced renal cell carcinoma | C64 | KDR; |
M00-M99: Diseases of the musculoskeletal system and connective tissue | Rheumatoid arthritis | M05-M06 | TYR; |
C00-D49: Neoplasms | Myelodysplastic syndrome | D46 | KDR; |
C00-D49: Neoplasms | Myelofibrosis | C94.4, D47.4 | FLT3; |
K00-K95: Diseases of the digestive system | Liver disease | K70-K77 | MET; |
C00-D49: Neoplasms | Head and neck cancer | C07-C14, C32-C33 | KDR; |
R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Growth failure | R62.8 | IGF1R; |
C00-D49: Neoplasms | Advanced malignancies | C00-C96 | KDR; |
I00-I99: Diseases of the circulatory system | Neurological disease | I21, I22, R52, R52.1-R52.2, R60.9, G89 | NPSR1; |
C00-D49: Neoplasms | Liver cancer | C22 | IGF1R; KDR; |
C00-D49: Neoplasms | Leukemia | C90-C95 | FLT3; |
C00-D49: Neoplasms | Myeloid leukemia | C92 | FLT3; |
C00-D49: Neoplasms | Cancer | C00-C96 | PIM1; MET; CDK1; IGF1R; KDR; NFKB1; FLT3; CA9; |
C00-D49: Neoplasms | Ovarian cancer | C56 | KDR; |
C00-D49: Neoplasms | Hepatocellular carcinoma | C22.0 | MET; IGF1R; KDR; |
NA: NA | Hematopoietic stem cell transplantation | NA | FLT3; |
C00-D49: Neoplasms | Hematological malignancies | C81-C86 | AURKB; |